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ABSTRACT
Pancreatic cancer is a recalcitrant malignancy, partly due to desmoplastic stroma which stimulates tumor
growth, invasion, and metastasis, and inhibits chemotherapeutic drug delivery. Transforming growth
factor-b (TGF-b) has an important role in the formation of stromal desmoplasia. The present study
describes the ability of color-coded intravital imaging to demonstrate the efﬁcacy of a TGF-b inhibitor to
target stroma in an orthotopic mouse model of pancreatic cancer. The BxPC-3 human pancreatic
adenocarcinoma cell line expressing green ﬂuorescent protein (GFP), which also has a high TGF-b
expression level, was used in an orthotopic model in transgenic nude mice ubiquitously expressing red
ﬂuorescent protein (RFP). Fourteen mice were randomized into a control group (n D 7, vehicle, i.p., weekly,
for 3 weeks) and a treated group (n D 7, SB431542 [TGF-b receptor type I inhibitor] 0.3 mg, i.p., weekly, for
3 weeks). Stromal cells expressing RFP and cancer cells expressing GFP were observed weekly for 3 weeks
by real-time color-coded intravital imaging. The RFP ﬂuorescence area from the stromal cells, relative to
the GFP ﬂuorescence area of the cancer cells, was signiﬁcantly decreased in the TGF-b-inhibitor-treatment
group compared to the control group. The present study demonstrated color-coded imaging in an
orthotopic pancreatic-cancer cell-line mouse model can readily detect the selective anti-stromal-cell
targeting of a TGF-b inhibitor.
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Introduction
Pancreatic cancer is a recalcitrant disease with a 5-year overall
survival of 6% despite multimodality treatments available.1
Pancreatic cancer is characterized by desmoplastic stroma2 that
stores and releases growth factors such as transforming growth
factor-b (TGF-b), ﬁbroblast growth factor (FGF), and insulin-
like growth factor-1 (IGF-1), which facilitate tumor growth,
invasion, and metastasis.3 In addition, increased interstitial
ﬂuid pressure induced by the desmoplastic stroma compresses
intratumor blood vessels, resulting in inhibition of chemothera-
peutic drug delivery and reduction of efﬁcacy.4 TGF-b plays a
central role for establishment of the desmoplastic stroma.5
Our laboratory has developed color-coded intravital and non-
invasive imaging using spectrally-distinct ﬂuorescent proteins, to
distinguish cancer and stromal cells in mouse models of cancer.6-9
Using color-coded imaging, we have demonstrated that stromal
cells are drivers for metastasis.10 We have also demonstrated using
color-coded imaging that stromal cells, such as pancreatic-cancer
stellate cells from the primary pancreatic tumor, accompany the
cancer cells to distant metastatic sites.11 We also showed by non-
invasive imaging that acquired ﬂuorescent protein-expressing stro-
mal cells can continuously proliferate within the growing tumor.12
In addition, we showed by non-invasive color-coded imaging the
intimate relationship of cancer and stromal cells and how each are
killed by standard chemotherapy.13
In the present report, we demonstrate that color-coded
imaging could detect selective stromal targeting by a TGF-b
antagonist in an orthotopic mouse model of pancreatic cancer.
Results and discussion
Color-coded imaging demonstrates that a TGF-b inhibitor
selectively targets stromal cells in orthotopic pancreatic
tumors
An orthotopic mouse model of human pancreatic cancer with
red ﬂuorescent protein (RFP)-expressing stromal cells and
green ﬂuorescent protein (GFP)-expressing cancer cells was
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established (Fig. 1). The RFP-expressing stromal-cell area of
tumors treated with the TGF-b inhibitor SB431542 gradually
decreased as demonstrated by time-course color-coded intravi-
tal imaging (Fig. 2, Fig. 3). The percentage of the RFP ﬂuores-
cence area from the stromal cells relative to the total
ﬂuorescence area was signiﬁcantly lower in the TGF-b inhibi-
tor-treated group from days 7 to 21 (Fig. 3, Fig. 4). Stromal
area did not decrease from days 7 to 21 in the untreated control
group (Fig. 2, Fig. 4).
Excised whole tumors and frozen sections made from them,
showed signiﬁcantly lower stroma area in the TGF-b-treated
tumors than control tumors (TGF-b inhibitor-treated: 34.7 §
2.6% stromal ﬂuorescent area, control: 54.0 § 9.4% stromal
ﬂuorescent area, P < 0.001), conﬁrming the results from real-
time intravital imaging (Fig. 5).
Frozen ﬂuorescent sections and H&E stained slides of the
same area from resected tumor specimens were compared
(Fig. 6). The GFP-expressing area of the frozen sections corre-
sponded to viable cancer cell nests in the H&E stained slides,
and the RFP-expressing area of the frozen sections overlapped
with area of stromal cells in the H&E stained slides.
The present study used the BxPC-3-GFP pancreatic cancer
cell line orthotopically transplanted in nude mice. This cell line
has been very well characterized by our laboratory and it
behaves as a typical pancreatic cancer with regard to growth
and metastasis.14,15 With regard to changes in growth rates,
surface markers, expression of other genes, cell function, and
histology of epithelial or mesenchymal cancer cells, Cai et al.16
have found that GFP expression does not change these funda-
mental properties of the cells. The study of Cai et al.16 matches
our own experience that GFP or other ﬂuorescent proteins do
not alter the fundamental properties of cancer cells.9,17-19 In
addition, transgenic mice, expressing ﬂuorescent proteins in
almost all tissues behave normally and have a normal life span,
indicating that constitutive expression of ﬂuorescent proteins
in almost call the cells of a mouse does not alter their funda-
mental properties.7,8,20
The present manuscript is a proof-of-principle that an agent
could selectively target the stroma of a tumor in vivo as deter-
mined by color-coded imaging, in the present case, TGF-b1.
Future experiments will investigate the effects of TGF-b1 in
downstream targets.
In the present study, the cancer cells in the tumor are labeled
with GFP and stromal cells with RFP. Future experiments will
investigate the effects of a stromal inhibitor such as TGF-b on
individual-cell types within the stroma.
Tumor volume was not affected by TGF-b1. Perhaps this
was because cancer cell proliferation replaced inhibited stromal
Figure 1. Orthotopic pancreatic tumor and real-time intravital color-coded imaging system. A representative dual-color orthotopic pancreatic cancer mouse model in
bright ﬁeld (A), GFP (B), and RFP ﬂourescence (C). Images were obtained with the OV100 Small Animal Imaging System. The tumor (arrowheads) was exposed on the pan-
creas (arrows) through an incision (C). After cutting the tumor surface (D-F), mice were placed under the microscope for real- time color-coded intravital imaging with the
FV-1000 confocal microscope (G, H). BF; bright ﬁeld, GFP; green ﬂuorescent protein, RFP; red ﬂuorescent protein. Scale bars: 5 mm.
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cells to an extent. Future experiments will compare GFPC can-
cer-cell and RFPC stromal-cell number over time during stro-
mal-cell inhibition.
Previously-developed concepts and strategies of highly selec-
tive tumor targeting can take advantage of molecular targeting
of tumors, including tissue-selective therapy which focuses on
unique differences between normal and tumor tissues.21-26
Conclusions
The present study has demonstrated that real-time intravital
imaging of orthotopic pancreatic tumors could distinguish can-
cer and stromal cells expressing GFP and RFP, respectively.
With this capability of intravital color-coded imaging, it was
possible to demonstrate that the TGF-b antagonist SB431542
could selectively target stromal cells within the pancreatic
tumor in the orthotopic mouse model. Future experiments will
determine the individual cell types targeted by anti-stromal
therapy in the color-coded model described in the present
report.
Materials and methods
Cells
The human pancreatic cancer cell line BxPC-3 labeled with
green ﬂuorescent protein (GFP) was established as described
previously.14,15 BxPC-3 highly expressed TGF-b (Murakami,
T., Hiroshima, Y., Hoffman, R.M., unpublished data).
Mice
Transgenic red ﬂuorescent protein (RFP)-expressing
athymic nu/nu nude mice8 (AntiCancer Inc., San Diego, CA),
4–6 weeks old, were used in this study in accordance with the
principles and procedures outlined in the Guide for the Care
and Use of Laboratory Animals, 8th edition under Public Health
Service Assurance Number A3873–1. Animals were housed
with no more than 5 per cage in a barrier facility on a high efﬁ-
ciency particulate arrestance (HEPA)-ﬁltered rack under stan-
dard conditions of 12-hour light/dark cycles. The animals were
fed an autoclaved laboratory rodent diet. In order to minimize
any suffering of the animals, anesthesia and analgesics were
used for all surgical experiments. Animals were anesthetized by
subcutaneous injection of a 0.02 ml solution of 25 mg/kg keta-
mine, 19 mg/kg xylazine, and 0.60 mg/kg acepromazine male-
ate. The response of animals during surgery was monitored to
ensure adequate depth of anesthesia. The animals were eutha-
nized by CO2 inhalation on day 21.
Subcutaneous injection of BxPC-3-GFP cell injection
BxPC-3-GFP cells were harvested by trypsynization after
mono-layer culture and washed with medium. A total of 2 £
Figure 2. Color-coded real-time intravital cancer-cell/stromal-cell imaging in untreated tumors. Color-coded intravital imaging of a tumor in a control mouse (A-D). Intra-
vital images were obtained weekly. Upper panels show GFP-expressing cancer cells, middle panels show RFP-expressing stromal cells, and lower panels show merged
images with GFP and RFP. Scale bars: 1.0 mm.
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106 BxPC-3-GFP cells, suspended in 100 ml RPMI 1640
medium (Gibco Life Technologies, Grand Island, NY) with
50% Matrigel (Becton Dickinson, Franklin Lakes, NY) was
injected subcutaneously to the ﬂanks of RFP nude mice.
Establishment of dual-color ﬂuorescent pancreatic-cancer
model by surgical orthotopic implantation (SOI)
The subcutaneously grown tumors were harvested 3 weeks after
cell injection. Tumors were cut into 4 mm3 fragments. A 5 mm
left lateral incision was made in a transgenic RFP nude mouse.
A tumor fragment was sutured orthotopically on the pancreatic
tail using 8–0 nylon surgical sutures (Ethilon, Ethicon, Inc.,
NJ). The wound was closed with 6–0 nylon surgical suture
(Ethilon).27-30 Three weeks after orthotopic implantation, a
color-coded ﬂuorescent pancreatic-cancer mouse model was
established.
Imaging
Whole-tumor macro imaging was performed using the OV100
Small Animal Imaging System (Olympus, Tokyo, Japan).31
Figure 3. Color-coded real-time intravital cancer-cell/stroma-cell imaging after treatment with a TGF-b inhibitor. Color-coded tumor from a TGF-b inhibitor-treated mouse
(A-D). Upper panels show GFP-expressing cancer cells; middle panels show RFP-expressing stromal cells, and lower panels show merged images with GFP and RFP. Scale
bars: 1.0 mm.
Figure 4. Quantitation of cancer cells and stromal cells in TGF-b inhibitor-treated and control pancreatic tumors. A) Line graphs show the percentage of RFP-expressing
stromal area obtained by real-time intravital imaging in treated and untreated tumors. P < 0.05; P < 0.01; P < 0.001. Error bars: § SD. B) Line graphs show real
time increase of tumor volume in untreated and treated tumors.
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Bright-ﬁeld and GFP- and RFP-ﬂuorescence images were
obtained. The OV100 contains an MT-20 light source (Olympus
Biosystems, Planegg, Germany) and DP70 CCD camera (Olym-
pus). The OV100 was used for subcellular imaging in live mice.
The optics of the OV100 ﬂuorescence imaging system have been
specially developed for macroimaging as well as microimaging
with high light-gathering capacity. The instrument incorporates
a unique combination of high numerical aperture and long
working distance. Individually optimized objective lenses, par-
centered and parfocal, provide a 105-fold magniﬁcation range
for seamless imaging of the entire body down to the subcellular
level without disturbing the animal. The OV100 has the lenses
mounted on an automated turret with a high magniﬁcation
range of x1.6 to x16 and a ﬁeld of view ranging from 6.9 to
0.69 mm. The optics and antireﬂective coatings ensure optimal
imaging of multiplexed ﬂuorescent reporters in small animals.
High-resolution images were captured directly on a PC (Fujitsu
Siemens, Munich, Germany). Images were processed for con-
trast and brightness and analyzed with the use of Paint Shop Pro
8 and CellR (Olympus Biosystems).31
Intravital imaging
Confocal microscopy (Fluoview FV1000, Olympus Corp.,
Tokyo, Japan) was used for two- (x,y) and three-dimensional
(3D, x,y,z) high-resolution intravital imaging with a cw semi-
conductor laser at 473 nm for GFP and RFP excitation (New-
port-Spectra Physics, Irvine, CA). Deep tissue ﬂuorescence
imaging used the 20x/0.50 UPlan FLN and 40x/1.3 Oil Olym-
pus UPLAN FLN objectives.32
Intravital confocal imaging was performed four times:
before treatment, day 7, day 14, and day 21. After mice were
anesthetized by subcutaneous injection, a 5 mm left lateral inci-
sion was made. The pancreatic tail with a grown tumor was
exposed through the incision. The tumor surface was cut by a
scalpel and the capsule was removed in order to image the
inside of the tumor. After hemostasis, the mouse was set under
the FV1000 confocal microscope. The exposed tumor was
placed between a sterilized board and a slide glass, exerting a
slight pressure on the cut surface (Fig. 1). The entire cut surface
area was scanned for color-coded ﬂuorescence imaging of the
GFP expressing cancer cells and RFP expressing stromal cells.
The wound was closed with 6–0 nylon surgical sutures. Mice
were returned to their cages when they began to walk. The per-
centage of the RFP ﬂuorescence area from the stromal cells rel-
ative to the total ﬂuorescence area was calculated with ImageJ
v1.49f (National Institutes of Health, Bethesda, MD).
Figure 5. Color-coded imaging of resected tumors and frozen sections from TGF-b inhibitors-treated and control tumors. Bright-ﬁeld and ﬂuorescence images of whole
tumors were obtained with the OV100 Small Animal Imaging System (A). Representative images of frozen tumor sections in both groups imaged with the FV-1000 confo-
cal microscope (B). Bar graph shows the percentage of RFP stromal area determined from frozen-section imaging (C). P < 0.001. Scale bars: 5 mm in (A); 500 mm in
(B). Error bars: § SD.
Figure 6. Comparison of color-coded ﬂuorescent frozen sections and H&E-stained
sections. Left panel shows a frozen section from a tumor imaged with the FV-1000
confocal microscope. Right panel is an image of same tumor stained with H&E.
The GFP-expressing area in the frozen section overlapped with cancer cells in the
H&E-stained slides. The RFP-expressing area in the frozen section overlapped with
stromal cells in the H&E-stained slides. Scale bars: 200 mm.
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TGF-b inhibitor treatment
When the tumor diameter reached 7 mm, the mice (n D 14)
were randomized into a control group (n D 7, 200 ml of vehicle,
i.p., weekly, for 3 weeks) and a treated group (n D 7, SB431542
[ALK5] TGF-b1 inhibitor, Selleck chemicals, Houston, TX,
0.3 mg in 200 ml solution, i.p., weekly, for 3 weeks). Intraperito-
neal administration of TGF-b1 in each group was performed
on day 1, 8, and 15 using a 27-gauge needle.
Frozen sections
Resected tumors were washed with phosphate buffered saline
was then dried. Tumors were sliced to 2–3 mm thickness, then
embedded in Neg-50 Frozen Section Medium (Thermo Fisher
Scientiﬁc, Waltham, MA) and immediately frozen with liquid
nitrogen. Tissue sections (8 mm) were made with a cryostat
(Leica, Buffalo Grove, IL).
Fluorescence imaging of frozen sections
To conﬁrm results from intravital imaging, frozen sections,
derived from resected tumor specimens, were imaged with the
FV1000 confocal microscope. One slide from the center of each
tumor was imaged, since as the tumor center most likely accu-
rately reﬂects the characteristics of each tumor. The percentage
of RFP ﬂuorescent area from the stromal cells, relative to the
total ﬂuorescent area (GFP and RFP), was calculated with
ImageJ.
Histological examination
Hematoxylin and eosin (H&E) staining was performed accord-
ing to standard protocols: Fresh tumor specimens were ﬁxed in
10% formalin and embedded in parafﬁn before sectioning and
staining. Tissue sections were deparafﬁnized in xylene and
rehydrated in an ethanol series. H&E staining was performed
according to standard protocols. Histological examination was
performed with a BHS system microscope. Images were
acquired with INFINITY ANALYZE software (Lumenera Cor-
poration, Ottawa, Canada).
Statistical analysis
SPSS statistics version 21.0 was used for all statistical analyses
(IBM, New York City, NY, USA). Signiﬁcant differences for
continuous variables were determined using the Student’s
t-test. Both line graphs and bar graphs express the mean values
and error bars show standard deviation (SD). A probability
value of P  0.05 was considered statistically signiﬁcant.
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